tbuckley/cabot-search huggingface dataset:
Abstract 9150: Actigraphy-Derived Sleep Health Metrics and Biomarkers of Cardiovascular Disease Risk in Black/African American Smokers
Authors: Elissa K Hoopes, aditi satti, Benjamin Brewer, Rachel Blair, Adam Davey, Michael A Grandner, William B Farquhar, Freda Patterson
Journal: Circulation (2021)

Introduction: Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in Black/African American (BAA) adults, and to a greater extent in BAAs who smoke cigarettes. Sleep is an emergent predictor of CVD, yet the independent role of sleep health on CVD risk in BAA smokers is unclear. Thus, we tested the hypothesis that better sleep health metrics would be independently associated with more favorable biomarkers of CVD risk in midlife BAA smokers. Methods: BAA adults (n=226, 55.9±6.1y, 44% male) who were current smokers (≥1 cigarette in last month) without sleep-disordered breathing or severe lung disease completed 14 days of wrist actigraphy to assess sleep duration, efficiency, midpoint, and regularity (sleep midpoint standard deviation). Resting blood pressure (BP) and heart rate recovery (HRR; HR peak minus HR 1-min recovery from submaximal exercise) were assessed. Hypertension was defined as resting BP ≥130/80 mmHg, or use of antihypertensives. Multivariable regression models of systolic BP, diastolic BP, hypertension (yes/no), and HRR were generated to test associations between sleep metrics and CVD risk markers after adjusting for key covariates (see Table). Results: In adjusted models, achieving a healthy sleep duration (6-8 h/night) was associated with 62% lower odds of hypertension (vs. &lt;6 or &gt;8h/night; OR=0.38, 95% CI=0.18-0.75). Later sleep midpoint was associated with higher systolic BP (B=1.97 mmHg per 1-h delay in midpoint, 95% CI=0.17-3.81); longer sleep duration (B=1.89 bpm per 1-h increase in duration, 95% CI=0.39-3.39) and greater sleep efficiency (B=0.27 bpm per 1% increase in efficiency, 95% CI=0.08-0.46) were associated with greater HRR. Conclusions: Better sleep health metrics are associated with a lower CVD risk profile in BAA smokers, independent of important confounding factors. Sleep health may represent an auxiliary intervention target for ameliorating the CVD burden experienced by this at-risk group.
Towards Clinical Translation of Hematopoietic Cell Gene Editing for Treating Hyper-IgM Type 1
Authors: Valentina Vavassori, Elisabetta Mercuri, Genni Marcovecchio, Maria Carmina Castiello, Daniele Canarutto, Claudia Asperti, Aurelien Jacob, Luisa Albano, Elena Fontana, Eugenio Scanziani, Marina Radrizzani, Anna Villa, Pietro Genovese, Luigi Naldini
Journal: Blood (2021)
Outcome with Hypomethylating Agent and Venetoclax Combination in Patients with Chronic Myelomonocytic Leukemia
Authors: Somedeb Ball, Akriti G Jain, Luis E. E. Aguirre, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T. Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David Swoboda, Rami S. Komrokji, David A. Sallman
Journal: Blood (2021)
Erratum: Corrigendum: Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance
Authors: Luca A Lotta, Pawan Gulati, Felix R Day, Felicity Payne, Halit Ongen, Martijn van de Bunt, Kyle J Gaulton, John D Eicher, Stephen J Sharp, Jian'an Luan, Emanuella De Lucia Rolfe, Isobel D Stewart, Eleanor Wheeler, Sara M Willems, Claire Adams, Hanieh Yaghootkar, Nita G Forouhi, Kay-Tee Khaw, Andrew D Johnson, Robert K Semple, Timothy Frayling, John R B Perry, Emmanouil Dermitzakis, Mark I McCarthy, Inês Barroso, Nicholas J Wareham, David B Savage, Claudia Langenberg, Stephen O'Rahilly, Robert A Scott
Journal: Nature Genetics (2017)
Abstract 9339: Cardiac Fibroblasts Are Critically Involved in the Development of Heart Failure by Inducing Cardiomyocyte Senescence
Authors: Toshiyuki Ko, Seitaro Nomura, Kanna Fujita, Shintaro Yamada, Bo Zhang, Satoshi Hatsuse, Masahiro Satoh, Masaru Hatano, Hiroyuki Morita, Issei Komuro
Journal: Circulation (2021)

Introduction: Tissue fibrosis and cellular senescence are hallmarks of age-related diseases including heart failure, but it remains elusive whether there is a common pathway to induce both events. Besides, the clinical significance of the cellular senescence seen in heart failure also remains unclear. Methods and Results: Through single-cell RNA-seq, spatial transcriptomics, and genetic perturbation, we focused and elucidated the role of high-temperature requirement A serine peptidase 3 (Htra3) which is expressed specifically in cardiac fibroblast. We found that Htra3 governs the identity of quiescent cardiac fibroblasts through degradation of TGF-β. Expression of Htra3 was downregulated by pressure overload in cardiac fibroblasts. Htra3 deletion in the murine heart caused overactivation of TGF-β signalling which induced not only significant cardiac fibrosis, but also cardiomyocyte senescence through DNA damage accumulation by repressing DNA repair factors and activating NADPH oxidase Nox4. Overexpression of Htra3 in the murine heart inhibited TGF-β signalling and ameliorated cardiac dysfunction as well as fibrosis after pressure overload. Htra3-regulated spatio-temporal cardiac fibrosis and cardiomyocyte senescence were also observed specifically in infarct regions after myocardial infarction. Furthermore, the senescent transcriptional profile observed in Htra3 knock-out murine cardiomyocytes were also seen in the cardiomyocytes from end-stage heart failure patients. Integrative analyses of human single-cardiomyocyte transcriptome and plasma proteome revealed that IGFBP7, which is a cytokine downstream of TGF-β and secreted from senescent cardiomyocytes, was the most predictable marker of advanced heart failure. Conclusions: Htra3 is a critical regulator of cardiac fibrosis and also affects cardiomyocyte senescence through the intercellular signalling communication between cardiac fibroblasts and cardiomyocytes. Our findings highlight the previously unknown roles of cardiac fibroblasts in regulating cardiomyocyte senescence as well as cardiac fibrosis through the Htra3-TGF-β-IGFBP7 pathway, which would be a novel therapeutic target for heart failure.
Association of Combined Slow Gait and Low Activity Fragmentation With Later Onset of Cognitive Impairment
Authors: Qu Tian, Stephanie A. Studenski, Yang An, Pei-Lun Kuo, Jennifer A. Schrack, Amal A. Wanigatunga, Eleanor M. Simonsick, Susan M. Resnick, Luigi Ferrucci
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Among older people, slow walking is an early indicator of risk for Alzheimer disease (AD). However, studies that have assessed this association have not considered that slow walking may have different causes, some of which are not necessarily associated with higher AD risk. <h3>Objective</h3> To evaluate whether low activity fragmentation among older adults with slow gait speed indicates neurological causes of slow walking that put these individuals at higher risk of AD. <h3>Design, Setting, and Participants</h3> This prospective cohort study performed survival analyses using data from the Baltimore Longitudinal Study of Aging. Participants included 520 initially cognitively normal persons aged 60 years or older. New diagnoses of mild cognitive impairment (MCI) or AD were adjudicated during a mean (SD) follow-up of 7.3 (2.7) years. Initial assessment of gait speed and activity fragmentation occurred from January 3, 2007, to May 11, 2015, with follow-up completed on December 31, 2020. Data were analyzed from February 1 to May 15, 2021. <h3>Exposures</h3> Gait speed for 6 m and activity fragmentation assessed by accelerometry. <h3>Main Outcomes and Measures</h3> Associations of gait speed, activity fragmentation, and their interaction with incident MCI/AD were evaluated using Cox proportional hazards models, adjusted for covariates. <h3>Results</h3> Among the 520 participants (265 women [51.0%]; 125 Black participants [24.0%]; 367 White participants [70.6%]; mean [SD] age, 73 [8] years), MCI/AD developed in 64 participants. Each 0.05-m/s slower gait was associated with a 7% increase in risk of developing MCI/AD (hazard ratio [HR], 1.07 [95% CI, 1.00-1.15];<i>P</i> = .04). Activity fragmentation alone was not associated with MCI/AD risk (HR, 0.83 [95% CI, 0.56-1.23];<i>P</i> = .35), but there was a significant interaction between gait speed and activity fragmentation (HR, 0.92 [95% CI, 0.87-0.98];<i>P</i> = .01). At low activity fragmentation (−1 SD), each 0.05-m/s slower gait speed was associated with a 19% increase in hazard of developing MCI/AD (HR, 1.19 [95% CI, 1.07-1.32]), whereas at higher activity fragmentation (+1 SD), gait speed was not associated with MCI/AD (HR, 1.01 [95% CI, 0.93-1.10]). Among participants with slow gait, higher activity fragmentation was associated with higher odds of having lower extremity osteoarthritis (odds ratio, 1.31 [95% CI, 1.01-1.69]) and less decline in pegboard dominant hand performance (β = 0.026 [SE, 0.009];<i>P</i> &gt; .05). <h3>Conclusions and Relevance</h3> These findings suggest that frequent rests among older adults with slow gait speed are associated with lower risk of future MCI/AD and that this behavioral strategy is associated with a lower likelihood of subclinical neurological impairment.
Mutant <i>TP53</i> prevents Telomere Shortening in Acute Myeloid Leukemia
Authors: Adam Wahida, Stephan Hutter, Carmelo Gurnari, Sabine Stainczyk, Simona Pagliuca, Manja Meggendorfer, Thomas Laframboise, Claudia Haferlach, Wolfgang Kern, Frank Westermann, Lars Feuerbach, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2021)
The Disparity Observed Between Murine Short-term and Long-term Hematopoietic Stem Cells in Their Ability to Migrate and Engraft When Introduced IV is Due to Distinct Adhesion Molecule Expression
Authors: Asma Al-Amoodi, Yanyan Li, Arwa A Alghuneim, Hanaa Allehaibi, Luke Esau, Jasmeen S. Merzaban
Journal: Blood (2021)
Monitoring of Circulating Tumor Plasma Cells in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Authors: Jón Þórir Óskarsson, Iris Petursdottir, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Gudrun Asta Sigurdardottir, Asdis Rosa Thordardottir, Gauti Kjartan Gislason, Andri Olafsson, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Robert Palmason, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Brian G.M. Durie, Thorvardur Jon Love, Sigurdur Y Kristinsson
Journal: Blood (2021)
Abstract P290: Short-term Weight Change and Long-term Mortality in the Trials of Hypertension Prevention
Authors: Nancy R Cook, Lawrence J Appel, Paul K Whelton
Journal: Circulation (2016)

Introduction: Although weight loss has favorable effects on intermediate outcomes, such as blood pressure and insulin resistance, few studies have examined its effects on long-term outcomes including total mortality. Methods: In the Trials of Hypertension Prevention (TOHP) individuals aged 30-54 years with high normal BP were randomized to a weight loss intervention, to one of several other lifestyle or dietary supplement interventions, or to usual care. All participants from Phase 1 (1987-90) and Phase 2 (1990-5) were followed for mortality through 2013. The association of weight change during any of the interventions with long-term mortality up to 18-24 years after the trial periods was examined among 3828 participants who fell into a high baseline weight stratum, defined as body mass index at least 26 kg/m2 in men and 24 kg/m2 in women. Results and Conclusions: There were 1477 high-weight participants in Phase 1 and 2351 in Phase 2, of whom 21% and 50%, respectively, were assigned to a weight loss intervention. Overall, mean weight change during the trial period was -1.8 lbs (-0.8% of baseline body weight) over 1.5 years in Phase 1 and 1.6 lbs (0.8%) over 3-4 years in Phase 2. A total of 556 (15%) lost &gt; 5%, 1,101 (29%) lost &lt;=5%, 1,567 (41%) gained less than 5%, and 604 (16%) gained &gt; 5% in body weight. Corresponding hazard ratios (HRs) for total mortality were 0.82 (95% confidence interval (CI)=0.57-1.18), 0.94 (95% CI=0.72-1.23), 1.00 (reference), and 1.29 (95% CI=0.92-1.80) (p-trend = 0.046). There was a direct linear relationship with percent change in weight during the trial period and later mortality (HR=1.14 per 5% change, 95% CI=1.02-1.28, p=0.019). This association persisted throughout the course of mortality follow-up (Figure). In these healthy individuals taking part in lifestyle and nutrition supplement trials , short-term weight change was directly associated with mortality about two decades later. These results are consistent with a long-term beneficial effect of presumed intentional weight loss on total mortality.
The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms' Tumor 1 Peptide Vaccination
Authors: Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko
Journal: Blood (2021)
How doctors are betraying the Hippocratic oath
Authors: Ian A Harris, Rachelle Buchbinder
Journal: BMJ (2021)

There are many respects in which the modern medical system is not fit for purpose and poses a threat to human health. In so many situations, our superficial assumptions about medicine are wrong. Having more tests to identify disease is often not better than leaving those "well enough" alone, labelling people with a specific disease may not be helpful, and more medicine may not be better than less medicine or no medicine at all.1 In our eagerness to intervene, we can end up doing harm. This fits with the estimation that around 30% of medical care is ineffective and another 10% is harmful.234 The common modern version of the Hippocratic Oath points to many of these problems. Quotes from the pledges and the problems they highlight include:
Trial in Progress: Phase I Open-Label Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma
Authors: Wilson I Gonsalves, Shaji Kumar, Gabriela Perez, Stephanie Saathoff, Diana M Wilson, Anna Young, Sikander Ailawadhi
Journal: Blood (2021)
Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases
Authors: Luke Maese, Mignon L. Loh, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Jeffrey A. Silverman, Mi Rim Choi, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau
Journal: Blood (2021)
Dysregulation of Epigenetic Landscape Uncovered the Mechanisms Underlying the Relapse of Pediatric Acute Lymphoblastic Leukemia with NSD2 Mutation
Authors: Jianping Li, Priscillia Lhoumaud, Alberto Riva, Crissandra Piper, Daphne Dupere-Richer, Heidi Casellas Roman, Amin Sobh, Charlotte L Kaestner, Alok Swaroop, Marta Kulis, Richard Lynn Bennett, Jane Skok, Jonathan D. Licht
Journal: Blood (2021)
A Meta-Analysis of Pivotal Pralatrexate Studies in Relapsed/Refractory Mature T-Cell Lymphoma (r/r TCL)
Authors: Owen A. O'Connor, Bor-Sheng Ko, Ming-Chung Wang, Dai Maruyama, Yuqin Song, Ee-Min Yeoh, Kensei Tobinai
Journal: Blood (2021)
Single-Cell Tracking By Time Lapse Imaging Confirms Thrombopoietin Promotes Megakaryocytic-Erythroid Progenitor Self Renewal, but Does Not Instruct Lineage Commitment
Authors: Vanessa M Scanlon, Maria Kochugaeva, Betty M Lawton, Juliana Xavier-Ferrucio, Elaine Kang, Nicole M Eskow, Yi-Chien Lu, Nayoung Kwon, Anisha Laumas, Matthew Cenci, Kalyani Lawrence, Katie Barden, Shannon M Larsuel, Fiona Reed, Gabriela Pena-Carmona, Ashley Ubbelohde, June P Lee, Shakthi Boobalan, Yvette Oppong, Rachel Anderson, Colby Maynard, Kaylie Sahirul, Callista Lajeune, Varsha Ivathraya, Tiffany Addy, Patricia Sanchez, Colin Holbrook, Andrew Tri Van Ho, Helen M. Blau, Andre Levchenko, Diane S. Krause
Journal: Blood (2021)
Adding the Cancer Genome Atlas Chromosome Classes to American Joint Committee on Cancer System Offers More Precise Prognostication in Uveal Melanoma
Authors: Maria Chiara Gelmi, Zeynep Bas, Kabir Malkani, Arupa Ganguly, Carol L. Shields, Martine J. Jager
Journal: Ophthalmology (2021)

Uveal melanoma (UM) is a rare disease and the most common primary intraocular malignancy in adults, with a high risk of metastases. Reliable prognostication systems are based on anatomic features, as in the tumor-node-metastasis staging of the American Joint Committee on Cancer (AJCC) system, or on genetic information, as in The Cancer Genome Atlas (TCGA) system. Prior evidence suggests that combining both systems may be beneficial. We evaluated the benefit of combining the TCGA and AJCC systems in a large cohort of patients.Retrospective case series of patients with UM.Nine hundred seventy-nine patients with a choroidal or ciliary body melanoma treated at the Wills Eye Hospital between 1998 and 2020, 94% of whom received eye-sparing treatment.Tumors were classified into 4 TCGA groups based on chromosome copy number: A (disomy 3, normal 8q), B (disomy 3, any 8q gain), C (monosomy 3, 1 extra copy of 8q), and D (monosomy 3, multiple 8q gain). The eighth edition of the AJCC staging manual was used for AJCC staging. Cox regression and the log-rank test were used for survival analysis.Metastasis-free survival.Combining information of the 2 systems improved prognostication in intermediate groups: in TCGA group C, we saw an increased rate of metastasis in AJCC stage III (28%) compared with stage II (8.9%); the same was seen in AJCC stage II, going from TCGA group C (8.9%) to group D (46%), and in AJCC stage III, going from group C (28%) to group D (49%). In patients with AJCC stage II or III disease, loss of chromosome 3 and gain of 8q (TCGA groups C and D) significantly worsened the prognosis, with multiple 8q gain (TCGA group D) having a greater impact.Combining information from AJCC stages and TCGA groups yields a better predictive power even in this set of relatively small tumors. We propose that physicians take both systems into account whenever possible, especially in moderate-risk groups.
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
Authors: Jiang Qian, Dayu Shi, Zongru Li, Yazhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood (2021)
Asciminib in Real-Life Clinical Practice, Safety and Efficacy Profile in Chronic Myeloid Leukemia Pretreated Patients
Authors: Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, Pilar Giraldo, Blanca Xicoy, Luis Felipe Casado, Fermin Sanchez-Guijo, Concepción Ruiz Nuño, Melania Moreno Vega, Alberto Alvarez-Larran, Araceli Salamanca Cuenca, Ana García-Noblejas, Ferran Vall-Llovera, Manuel Perez Encinas, Lucia Villalon, Natalia De las Heras, Sunil Lakhwani, Elena Ramila, Beatriz Cuevas, Raul Perez Lopez, Antonio Jiménez-Velasco, Ana Rosell, Angeles Escola, Maria Jose Fernández, Carmen Garcia-Hernandez, Carlos Cervero, Elvira Mora Casterá, Miguel Sagüés, Sara Suarez-Varela, Patricia Vélez, Patricia Carrascosa Mastell, Rocio Fé Bitaube, Luis Serrano, Montse Cortes, Juan Antonio Juan Vera Goñi, Juan Luis Steegmann, Juan Carlos Hernandez Boluda, Valle Gomez, Juan Manuel Alonso-Dominguez, Mercedes Colorado Araujo, Antonio Paz Coll, Valentín Garcia Gutierrez
Journal: Blood (2021)
Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies
Authors: George S. Laszlo, Johnnie J. Orozco, Allie R. Kehret, Margaret C. Lunn, Donald K. Hamlin, D. Scott Wilbur, Shannon L. Dexter, Melissa C. Comstock, Shyril O'Steen, Damian J. Green, Roland B. Walter
Journal: Blood (2021)
춘계학술대회 발표 : 구연 ; HBeAg 음성 만성 B형간염 환자에서 라미부딘 2년 투여 요법과 2년 이상 계속 투여 요법의 치료 효능에 대한 장기간 추적 결과
Authors: 김익성, 이관식, 백용한, 황성규, 김지현, 이현진, 강소희, 오석진, 안상훈, 한광협, 전재윤, 문영명
Journal: Clinical and Molecular Hepatology (2006)
FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation
Authors: Pamela J. Sung, Simone Sidoli, Simone S. Riedel, Katarzyna Kulej, Hongbo Xie, Bryan Manning, Daniel Tsai, Gerald Wertheim, Benjamin A. Garcia, Sara E. Meyer, Kathrin M. Bernt, Martin P. Carroll
Journal: Blood (2021)
BCL-Xl Driven Accumulation of Dysfunctional Mitochondria in Aged Stromal Cells Impairs the Haematopoietic Stem Cell Response to Stress
Authors: Charlotte Hellmich, Jayna J Mistry, Aisha Jibril, Jamie A Moore, Benjamin B Johnson, James G W Smith, Edyta Wojtowicz, Naiara Beraza, Kristian M Bowles, Stuart A Rushworth
Journal: Blood (2021)
Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis
Authors: Alexandra Rezazadeh, Aniko Szabo, Kathleen Monahan, Arushi Khurana, David J. Inwards, Matthew A. Lunning, Amanda Cashen, Nancy L. Bartlett, Paolo F. Caimi, Thomas D. Rodgers, Paul M. Barr, Sayan Mullick Chowdhury, Narendranath Epperla, Hiruni Mendries, Brian T. Hill, Timothy Seijung Oh, Reem Karmali, Julie E. Chang, Gaurav Goyal, Benjamin M Parsons, Krista M. Isaac, Craig A. Portell, Malika Siker, David M King, Timothy S. Fenske
Journal: Blood (2021)
Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network
Authors: Olivier Hermine, Linmiao Jiang, Jan Walewski, Andre Bosly, Michal Szymczyk, Catherine Thieblemont, Christiane Pott, Gilles Salles, Pierre Feugier, Kai Hübel, Barbara Burroni, Wolfram Klapper, Michael Unterhalt, Eva Hoster, Martin Dreyling
Journal: Blood (2021)
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study
Authors: Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg
Journal: Blood (2021)
Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma
Authors: Fan Yang, Hui Shi, Yang Lei, Ruiting Li, Teng Xu, Biping Deng, Tong Wu, Xiaoyan Ke, Kai Hu
Journal: Blood (2021)
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2
Authors: Sattva S. Neelapu, Mehdi Hamadani, Don Stevens, Sandra M. Hayes, Francesco Galimi, David B. Miklos
Journal: Blood (2021)